Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2147-2153

  Seto, Kahori ^a   Shoda, Junichi ^a   Horibe, Tomohisa ^b   Warabi, Eiji ^a   Ishige, Kazunori ^a   Yamagata, Kenji ^a   Kohno, Masayuki ^b   Yanagawa, Toru ^a   Bukawa, Hiroki ^a   Kawakami, Koji ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Head and neck squamous cell carcinoma; Hybrid peptide; Interleukin 4 receptor ; Molecular targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 4 RECEPTOR ALPHA; LYSYLGLUTAMINYLLEUCYLISOLEUCYLARGINYLPHENYLALANYLLEUCYLLYSYLARGINYLLEUCYLASPARTYLARGINYLASPARAGINYLGLYCYLGLYCYLGLYCYLLYSYLLEUCYLLEUCYLLEUCYLLYSYLLEUCYLLEUCYLLYSYLLYSYLLEUCYLLEUCYLLYSYLLEUCYLLEUCYLLYSYLLYSYLLYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GINGIVAL NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRALESIONAL; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PROTEIN BINDING; TONGUE NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876265361     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2387     Document Type: Article

References (27)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Seiwert TY and Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92: 1341-1348, 2005. (Pubitemid 40704997)
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003. (Pubitemid 37464533)
4. Dietz A, Boehm A, Mozet C, Wichmann G and Giannis A: Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265 (Suppl 1): S3-S12, 2008.
5. Price KA and Cohen EE: Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13: 35-46, 2012.
6. Kirby AM, A'Hern RP, D'Ambrosio C, et al: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94: 631-636, 2006. (Pubitemid 43361892)
7. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578-5587, 2005.
8. Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR and Puri RK: Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res 67: 9903-9912, 2007. (Pubitemid 47621239)
9. Ishige K, Shoda J, Kawamoto T, et al: Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer 123: 2915-2922, 2008.
10. Pastan I, Hassan R, Fitzgerald DJ and Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559-565, 2006. (Pubitemid 43980544)
11. Weber f, Asher A, Bucholz R, et al: Safty, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64: 125-137, 2003.
12. Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I and Rosenberg SA: Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 29: 208-214, 2006.
13. Choudhary S, Mathew M and Verma RS: Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16: 495-503, 2011.
14. Kohno M, Horibe T, Haramoto M, et al: A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 47: 773-783, 2011.
15. Garland L, Gitlitz B, Ebbinghaus S, et al: Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 28: 376-381, 2005. (Pubitemid 40962331)
16. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001. (Pubitemid 33716564)
17. Goon PK, Stanley MA, Ebmeyer J, et al: HPV & head and neck cancer: a descriptive update. Head Neck Oncol 1: 36, 2009.
18. Bosch F and Rosich L: The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 82: 171-179, 2008.
19. Pastan I, Hassan R, FitzGerald DJ and Kreitman RJ: Immunotoxin treatment of cancer. Annu Rev Med: 221-237, 2007. (Pubitemid 46706511)
20. Kreitman RJ: Immunotoxins for targeted cancer therapy (review). AAPS J 8: 532-551, 2006.
21. Li Z, Yu T, Zhao P and Ma J: Immunotoxins and cancer therapy. Cell Mol Immunol 2: 106-112, 2005.
22. Horibe T, Kohno M, Haramoto M, Ohara K and Kawakami K: Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 9: 8, 2011.
23. Tada N, Horibe T, Haramoto M, Ohara K, Kohno M and Kawakami K: A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem Biophys Res Commun 407: 383-388, 2011.
24. Strome SE, Kawakami K, Alejandro D, et al: Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin Cancer Res 8: 281-286, 2002. (Pubitemid 34101489)
25. Mehrotra R, Varricchio F, Husain SR and Puri RK: Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ. Oncol Rep 5: 45-48, 1998.
26. Kawakami K, Leland P and Puri RK: Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 60: 2981-2987, 2000. (Pubitemid 30395824)
27. Mimeault M, Hauke R, Mehta PP and Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11: 981-1011, 2007. (Pubitemid 350037046)